KR102007633B1 - 신규 페닐 프로피온 산 유도체 및 이의 용도 - Google Patents

신규 페닐 프로피온 산 유도체 및 이의 용도 Download PDF

Info

Publication number
KR102007633B1
KR102007633B1 KR1020170171228A KR20170171228A KR102007633B1 KR 102007633 B1 KR102007633 B1 KR 102007633B1 KR 1020170171228 A KR1020170171228 A KR 1020170171228A KR 20170171228 A KR20170171228 A KR 20170171228A KR 102007633 B1 KR102007633 B1 KR 102007633B1
Authority
KR
South Korea
Prior art keywords
oxy
dihydro
inden
pyridin
hex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170171228A
Other languages
English (en)
Korean (ko)
Other versions
KR20180069718A (ko
Inventor
강재훈
이홍섭
안경미
홍창희
곽현정
최석림
송효정
Original Assignee
일동제약(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020170171228A priority Critical patent/KR102007633B1/ko
Application filed by 일동제약(주) filed Critical 일동제약(주)
Priority to JP2019531649A priority patent/JP6892922B2/ja
Priority to PT178808721T priority patent/PT3555076T/pt
Priority to US16/467,654 priority patent/US11225472B2/en
Priority to FIEP17880872.1T priority patent/FI3555076T3/fi
Priority to EP17880872.1A priority patent/EP3555076B1/en
Priority to AU2017374460A priority patent/AU2017374460B2/en
Priority to BR112019012433A priority patent/BR112019012433A2/pt
Priority to SI201731367T priority patent/SI3555076T1/sl
Priority to PCT/KR2017/014757 priority patent/WO2018111012A1/en
Priority to HUE17880872A priority patent/HUE062468T2/hu
Priority to NZ753053A priority patent/NZ753053B2/en
Priority to PL17880872.1T priority patent/PL3555076T3/pl
Priority to ES17880872T priority patent/ES2948485T3/es
Priority to MYPI2019003388A priority patent/MY198292A/en
Priority to CN201780074801.4A priority patent/CN110049984B/zh
Priority to RS20230456A priority patent/RS64259B1/sr
Priority to MX2019007071A priority patent/MX2019007071A/es
Priority to DK17880872.1T priority patent/DK3555076T3/da
Priority to RU2019121871A priority patent/RU2760266C2/ru
Priority to IL267239A priority patent/IL267239B/en
Priority to CA3042528A priority patent/CA3042528C/en
Publication of KR20180069718A publication Critical patent/KR20180069718A/ko
Priority to PH12019501251A priority patent/PH12019501251A1/en
Application granted granted Critical
Publication of KR102007633B1 publication Critical patent/KR102007633B1/ko
Priority to US17/523,652 priority patent/US11731961B2/en
Priority to US17/559,546 priority patent/US20220112185A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y10S514/866—
    • Y10S514/909—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020170171228A 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도 Active KR102007633B1 (ko)

Priority Applications (25)

Application Number Priority Date Filing Date Title
KR1020170171228A KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도
CN201780074801.4A CN110049984B (zh) 2016-12-15 2017-12-14 苯基丙酸衍生物及其用途
US16/467,654 US11225472B2 (en) 2016-12-15 2017-12-14 Phenyl propionic acid derivatives and uses thereof
FIEP17880872.1T FI3555076T3 (fi) 2016-12-15 2017-12-14 Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja
EP17880872.1A EP3555076B1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof
AU2017374460A AU2017374460B2 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof
BR112019012433A BR112019012433A2 (pt) 2016-12-15 2017-12-14 compostos, composição farmacêutica para a prevenção ou tratamento de distúrbios metabólicos e uso de compostos
SI201731367T SI3555076T1 (sl) 2016-12-15 2017-12-14 Novi derivati fenil propionske kisline in njihove uporabe
PCT/KR2017/014757 WO2018111012A1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof
HUE17880872A HUE062468T2 (hu) 2016-12-15 2017-12-14 Új fenilpropionsav-származékok és alkalmazásaik
NZ753053A NZ753053B2 (en) 2016-12-15 2017-12-14 Phenyl propionic acid derivatives and uses thereof
PL17880872.1T PL3555076T3 (pl) 2016-12-15 2017-12-14 Nowe pochodne kwasu fenylopropionowego i ich zastosowania
JP2019531649A JP6892922B2 (ja) 2016-12-15 2017-12-14 新規フェニルプロピオン酸誘導体及びその用途
MYPI2019003388A MY198292A (en) 2016-12-15 2017-12-14 Novel Phenyl Propionic Acid Derivatives and uses Thereof
MX2019007071A MX2019007071A (es) 2016-12-15 2017-12-14 Novedosos derivados del acido fenilpropionico y usos de los mismos.
IL267239A IL267239B (en) 2016-12-15 2017-12-14 New derivatives of phenylpropionic acid and their uses
RS20230456A RS64259B1 (sr) 2016-12-15 2017-12-14 Novi derivati fenil propionske kiseline i njihova primena
DK17880872.1T DK3555076T3 (da) 2016-12-15 2017-12-14 Nye phenylpropionsyrederivater og anvendelser deraf
RU2019121871A RU2760266C2 (ru) 2016-12-15 2017-12-14 Новые производные фенилпропионовой кислоты и их применение
PT178808721T PT3555076T (pt) 2016-12-15 2017-12-14 Novos derivados de ácido fenilpropiónico e utilizações dos mesmos
CA3042528A CA3042528C (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof
ES17880872T ES2948485T3 (es) 2016-12-15 2017-12-14 Nuevos derivados del ácido fenilpropiónico y usos de los mismos
PH12019501251A PH12019501251A1 (en) 2016-12-15 2019-06-06 Novel phenyl propionic acid derivatives and uses thereof
US17/523,652 US11731961B2 (en) 2016-12-15 2021-11-10 Phenyl propionic acid derivatives and uses thereof
US17/559,546 US20220112185A1 (en) 2016-12-15 2021-12-22 Novel phenyl propionic acid derivatives and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160171541 2016-12-15
KR20160171541 2016-12-15
KR1020170171228A KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20180069718A KR20180069718A (ko) 2018-06-25
KR102007633B1 true KR102007633B1 (ko) 2019-08-06

Family

ID=62559593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170171228A Active KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도

Country Status (22)

Country Link
US (2) US11225472B2 (enExample)
EP (1) EP3555076B1 (enExample)
JP (1) JP6892922B2 (enExample)
KR (1) KR102007633B1 (enExample)
CN (1) CN110049984B (enExample)
AU (1) AU2017374460B2 (enExample)
BR (1) BR112019012433A2 (enExample)
CA (1) CA3042528C (enExample)
DK (1) DK3555076T3 (enExample)
ES (1) ES2948485T3 (enExample)
FI (1) FI3555076T3 (enExample)
HU (1) HUE062468T2 (enExample)
IL (1) IL267239B (enExample)
MX (1) MX2019007071A (enExample)
MY (1) MY198292A (enExample)
PH (1) PH12019501251A1 (enExample)
PL (1) PL3555076T3 (enExample)
PT (1) PT3555076T (enExample)
RS (1) RS64259B1 (enExample)
RU (1) RU2760266C2 (enExample)
SI (1) SI3555076T1 (enExample)
WO (1) WO2018111012A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024123015A1 (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019191624A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4329756A1 (en) * 2021-04-29 2024-03-06 Ildong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
WO2022269439A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
WO2023080299A1 (ko) * 2021-11-08 2023-05-11 일동제약(주) 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086661A2 (en) 2004-02-27 2005-09-22 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2006130707A2 (en) 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
JP5055852B2 (ja) 2006-06-21 2012-10-24 住友大阪セメント株式会社 鉄資源の回収方法
HUE025363T2 (en) * 2010-12-01 2016-02-29 Boehringer Ingelheim Int Indanyl Oxide Hydrobenzofuranylacetic Acids that can be used to treat metabolic syndrome
JP2013147443A (ja) * 2012-01-18 2013-08-01 Daiichi Sankyo Co Ltd β置換カルボン酸誘導体
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
JP6533778B2 (ja) * 2013-09-26 2019-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
WO2017180457A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Gpr40 agonists in anti-diabetic drug combinations
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
EP4329756A1 (en) * 2021-04-29 2024-03-06 Ildong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
WO2022269439A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
US20230022803A1 (en) * 2021-06-25 2023-01-26 Ildong Pharmaceutical Co., Ltd. Novel crystalline form of gpr40 agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086661A2 (en) 2004-02-27 2005-09-22 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2006130707A2 (en) 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 2002, Vol. 22, pp. 1267~1270
Bioorganic & Medicinal Chemistry Letters, 2011, Vol. 21, pp. 3390~3394
Molecular Diversity, 2014, Vol. 18, pp.183~193

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024123015A1 (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
US11225472B2 (en) 2022-01-18
RS64259B1 (sr) 2023-07-31
PT3555076T (pt) 2023-06-30
HUE062468T2 (hu) 2023-11-28
EP3555076A4 (en) 2019-10-23
CA3042528A1 (en) 2018-06-21
EP3555076A1 (en) 2019-10-23
AU2017374460A1 (en) 2019-05-23
JP2020502111A (ja) 2020-01-23
US20220064154A1 (en) 2022-03-03
ES2948485T3 (es) 2023-09-13
PL3555076T3 (pl) 2023-08-21
JP6892922B2 (ja) 2021-06-23
BR112019012433A2 (pt) 2020-04-14
RU2019121871A3 (enExample) 2021-01-15
IL267239A (en) 2019-08-29
KR20180069718A (ko) 2018-06-25
WO2018111012A1 (en) 2018-06-21
EP3555076B1 (en) 2023-04-05
DK3555076T3 (da) 2023-06-19
US20200223833A1 (en) 2020-07-16
CN110049984A (zh) 2019-07-23
MX2019007071A (es) 2019-08-01
AU2017374460B2 (en) 2020-08-20
RU2760266C2 (ru) 2021-11-23
FI3555076T3 (fi) 2023-06-28
NZ753053A (en) 2021-01-29
CA3042528C (en) 2022-03-08
IL267239B (en) 2022-07-01
MY198292A (en) 2023-08-21
CN110049984B (zh) 2022-11-15
SI3555076T1 (sl) 2023-09-29
RU2019121871A (ru) 2021-01-15
US11731961B2 (en) 2023-08-22
PH12019501251A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
KR102007633B1 (ko) 신규 페닐 프로피온 산 유도체 및 이의 용도
TWI843243B (zh) 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
TW202200559A (zh) Ｇｌｐ－１受體促效劑、包含該促效劑之醫藥組成物及其製備方法
JP5654675B2 (ja) ピペリジン誘導体及び代謝障害の治療のためのそれらの使用
JP7170996B2 (ja) スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2008029217A2 (en) Dipeptidyl peptidase iv inhibitors
JP5331953B2 (ja) 代謝性障害の治療のための３−アミノ−ピリジン誘導体
KR20220140429A (ko) Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
US20220112185A1 (en) Novel phenyl propionic acid derivatives and uses thereof
WO2025021048A1 (zh) 一类多环化合物及其用途
KR102377981B1 (ko) 폐 섬유증 치료용 조성물
US20250368619A1 (en) Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
EP4508028B1 (en) Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
NZ753053B2 (en) Phenyl propionic acid derivatives and uses thereof
CN121378215A (zh) 新骨架小分子化合物及应用

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20171213

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181218

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190729

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190731

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190801

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220705

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240729

Start annual number: 6

End annual number: 6